| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: VGNX |
| Security Type |
Common Stock |
| Lead Underwriter |
CS First Boston Corp |
| Days In Registration |
114 |
| Date Filed |
29-Mar-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company, focusing on the development of pharmaceuticals targeted to the normal genetic variation of human populations |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
23.1M |
| President and CEO |
Taylor J. Crouch |
| Number of Employees |
51 |
|
| Original Filing Information |
| US |
| Shares Filed |
5.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$60.0M |
| File Price Range |
$13.00 - $11.00 |
| File Mid Price |
$12.00 |
Current Filing Information
(Amended 20-Jul-2000) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$60.0M |
| · % Change from Original |
0.0 |
| File Price Range |
$13.00 - $11.00 |
| File Mid Price |
$12.00 |
|
